Sirotinib Maleate

马来酸赛罗替尼

Report date: 2026/05/08 20:02:52

NME

Base Information

Drug NameSirotinib Maleate

Drug Alias NameXZP-5491

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitorsReceptor tyrosine-protein kinase erbB-3 inhibitors +[4]

TargetsReceptor protein-tyrosine kinase erbB-4Epidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2 +[4]

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsCarcinoma, Squamous Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesShandong Xuanzhu Pharmaceutical Technology Co Ltd

China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShandong Xuanzhu Pharmaceutical Technology Co Ltd

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsCarcinoma, Squamous Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A